Healthcare Industry Insights: April 2023

Friday 28 April 2023

Preimplantation Genetic Testing Market Worth $107.3 Million By 2024

The global Preimplantation Genetic Testing Market is expected to reach USD 107.3 million by 2024, at a CAGR of 6.2% over the forecast period, according to a new report by Grand View Research, Inc. It is primarily driven by a rising awareness among couples to undergo diagnostic and screening tests to minimize genetic diseases and aneuploidy in fetus. The ability of preimplantation genetic testing to detect genetic disorders and rare diseases, such as fibrodysplasia ossificans progressive, is anticipated to propel the growth.

High adoption of In Vitro Fertilization (IVF) technique consequently upsurges the utilization of Preimplantation Genetic Diagnosis (PGD). These techniques are advantageous in a way that they allow the development of a healthy fetus and prevent the risk of selective pregnancy termination. Hence, PGT acts as an addendum to assisted reproductive technology.

A substantial number of patients with infertility and impaired fecundity are recommended to embrace IVF therapy in combination with PGT procedures, which in turn is expected to stimulate the growth. In addition, public and private authorities are promoting reproductive health by undertaking initiatives is also anticipated to drive the Preimplantation Genetic Testing (PGT) (PGS/PGD) market.

Related Press Release@ Preimplantation Genetic Testing Market

Preimplantation Genetic Testing Market Report Highlights

· Availability of a significant number of services related to early diagnosis of specific gene mutation in embryo marked the dominant position of PGD in 2018

· Preimplantation Genetic Screening (PGS) seems to be reasonable intervention to enhance efficiency of selecting chromosomally normal embryo during IVF cycles. It is increasingly being applied for embryo screening due to ever-expanding IVF, which is projected to create lucrative growth opportunities in near future

Advancements in detection of chromosomal anomalies by executing non-invasive prenatal testing results in a maximum share of this segment in 2018
Expanding utilization rate of FISH probe sets and benefits associated with the detection of a single-gene disorder is expected to fuel the growth of X-linked diseases segment
Implementation of PGT in embryo HLA typing for stem cell therapy is expected to impose segment growth. This is further attributed to the advantages pertaining to PGS testing for identification of HLA compatible embryos during stem cell therapy
Europe accounts for largest revenue share in 2018 owing to increased usage of PGD and PGS for the delivery of genetically healthy offspring during IVF procedures
Asia Pacific market is observed to reveal the fastest CAGR due to the rise in medical tourism and the continuous development of IVF and PGD clinics in Asian countries
Key players that have commercialized PGT services include Natera, Inc.; CooperSurgical, Inc.; F. Hoffmann-La Roche AG; Illumina, Inc.; IGENOMIX; and others
Key participants are actively involved in expansion of the distribution network for their products as well as R&D activities for the development of novel PGT services. In October 2018, Illumina Inc. signed an agreement with Vitrolife AB under which Vitrolife act as a distributor supplier of Illumina’s PGT products in EMEA and America.

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Tele Incentive Care Unit Market Size is Predicted to Witness 16.7% CAGR till 2026

The global Tele Intensive Care Unit Market size is expected to reach USD 6.1 billion by 2026, according to a new report by Grand View Research, Inc., expanding at a CAGR of 16.7% over the forecast period. Increase in demand for remote patient monitoring with ever-rising old age population, coupled with technological innovations, is the prime factor responsible for the tele intensive care unit (ICU) market growth. As per statistics published by the National Institutes of Health (NIH), in 2016, around 617.0 million people were aged above 65, accounting for 8.5% of the global population.

Moreover, the world report on aging published in 2015 stated that 17.0% of the global population would be above 65 by 2050. In U.S., the population aged 65 or above is expected to reach 88 million by 2050. Old age people are more prone to health-related issues, so hospitalization rate is high in this age group, which may lead to surgeries and use of ICU units.

Tele incentive care unit increases efficiency in healthcare delivery, streamlines clinical decision time, and enables real-time access for the patient’s health records. This, in turn, boosts demand for the tele intensive care unit enabled services. In addition, the advantage of implementing tele intensive care unit is the reduction in hospital stays and decrease in the overall costs incurred by the patients. However, major obstacles in the market growth are low adoption of technology and high implementation costs of the system.

Related Press Release@ Tele Intensive Care Unit Market

Tele Intensive Care Unit Market Report Highlights

The hardware component products emerged as the largest segment in 2018, accounting for a share of 86.2%, owing to technical innovations in the components. Physiological monitors held the largest share in the hardware segment. The software segment expected to register the highest CAGR of 18.7% over the forecast period
North America dominated the market with the largest share in 2018. Regulatory requirements in this region are fueling the market growth. The presence of super specialty hospitals, growing adoption, and awareness among consumers are favoring market growth in the region
Asia Pacific is expected to witness substantial growth owing to unmet needs of the huge population base and improving healthcare infrastructure
Some of the players operating in the market are Advanced ICU Care, Banner Health, InTouch health, Philips, iMDsoft, UPMC Italy, INTELEICU, Tele ICU, INOVA, and VISICU.

RFID in Healthcare Market Worth $10.65 Billion By 2025 | CAGR: 22.4%

The global RFID In Healthcare Market size is expected to reach USD 10.65 Billion by 2025, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 22.4% during the forecast period. Some of the key contributors to the growth include rising focus on reducing operational costs and streamline the workflow, demand for efficient supply chain management, and need to improve the quality and efficiency of care.

High operational costs associated with the healthcare industry is expected to boost the adoption of RFID technology in healthcare organizations. Pharmaceutical companies, medical device manufacturers, hospitals, and various other healthcare organizations integrate this technology to control inventory costs. RFID technology enables these organizations in efficient inventory management and help avoid stock out and overstock situations. RFID tags enable the surgical staff in easy tracking of medical devices used in operation theatres, thereby improving patient safety. Growing requirement for reduction in operating costs is expected to drive the increase in adoption of RFID. This technology is also used in laboratories, blood banks, and pathology labs for efficient product tracking and better workflow management.

The use of RFID technology enables better communication, adequate patient monitoring, patient identification, and patient tracking. This method aids in decreasing medication errors and increases safety. The rising need for patient monitoring and mandates for increasing safety are also contributing to the growth. Patient tracking across different hospital sections using this technology helps reduce waiting times and is thus gaining significance in hospitals.

Related Press Release@ RFID in Healthcare Market

RFID in Healthcare Market Report Highlights

RFID tags product segment held majority of the market share in 2018 due to rising awareness regarding the benefits of these devices
Increasing use of tags for tracking various assets, patients, staff, pharmaceuticals, and donated blood is expected to boost the market during the forecast period
Pharmaceutical tracking application segment held the largest market share in 2018, owing to rising needs to identify counterfeit drugs and demand for inventory management
North America led the global market owing to increasing number of hospitals and presence of regulations on patient safety
Asia Pacific is anticipated to witness the fastest CAGR owing to the presence of a large pharmaceutical industry requiring this technology for process streamlining
Some of the key players operating in the RFID in healthcare market include LogiTag, CenTrak, SpaceCode, Impinj, Zebra Technologies Corporation, Biolog-id, Terso Solutions, Carinal Health, Mobile Aspects, Tagsys RFID, Pepperl+Fuchs, and metraTec GmbH

Sperm Bank Market: Industry Demand, Analysis And Future Trends 2025

The global Sperm Bank Market size is expected to reach USD 5.45 billion by 2025, at a CAGR of 3.3% over the forecast period, according to a new report by Grand View Research, Inc. The market is majorly driven by increasing incidence of male andfemale infertility, rising acceptance of sperm banking services, and government initiatives in Assisted Reproductive Techniques (ART). Increasing cases of miscarriage is also one of the key growth contributors.

According to the female age-related infertility study by the American Society for Reproductive Medicine (ASRM), fertility decreases with age. Risks of complications during pregnancy also increase with age, resulting in the use of donor sperms or eggs. Rising trend of smoking is also affecting fertility in males and females. Female smokers achieve menopause earlier as compared to nonsmokers and are also at higher risk of miscarriage. This also represents lucrative opportunities for the market growth.

Rise in funding and supportive initiatives for ART has driven growth of the sperm bank market. For instance, the Australian government funds the ART services under the Medicare Benefit Scheme. It supports the access to In vitro Fertilization (IVF) or ART for the people unable to have children. Other countries with supportive initiatives include U.K., Singapore, and Canada.

Growing acceptance of Lesbian, Gay, Bisexual, and Transgender (LGBT) community is also a key market driver. The Human Rights Campaign (HRC) reports that the LGBT community is growing in U.S., and a survey states that more than 10,000 LGBT identified youth are aged between 13 and 17 years. This represents growing demand for sperm banking services in the country.

Related Press Release@ Sperm Bank Market

Sperm Bank Market Report Highlights

In 2018, known donor segment held the largest market share in terms of revenue owing to legal framework in various countries against donor anonymity
Semen analysis accounted for the highest revenue share in 2018. However, sperm storage segment is expected to expand at the faster CAGR over the forecast period
In vitro fertilization held the largest revenue share in terms of end use, in 2018 and is anticipated to expand at a CAGR of 3.3% over the forecast period
Asia pacific is expected to register the fastest CAGR over the forecast period owing to the growing fertility tourism and low cost of the procedure
Key players operating in the sperm bank market include Fairfax Cryobank, Inc.; Cryo-Save AG; Andocryos; New England Cryogenic Center; Indian Spermtech; Seattle Sperm Bank; Xytex Corporation; and London Sperm Bank.

Epigenetics Market: Industry Demand, Analysis And Future Trends 2025

The global Epigenetics Market size is expected to reach USD 22.05 billion by 2025, according to a new study by Grand View Research, Inc., progressing at a CAGR of 19.7% during the forecast period. The growing prevalence of cancer and other diseases worldwide with an epigenetic modification base is expected to drive the market during the forecast period.

Diagnostic companies are coming up with new products such as antibodies specific for the detection of modifications and new upgraded kits for easy and efficient detection of biomarkers. This is estimated to attract pharmaceutical companies to collaborate for the development of therapeutic drugs, which will work in favor of the market.

The presence of pipeline drugs and their expected commercialization is anticipated to boost the growth of the market. For instance, Ramucirumab (Cyramza) by Eli Lilly and Company was approved by the FDA for use in combination with Folfiri for the treatment of patients with metastatic colorectal cancer.

Technology advancements in the epigenetics industry are majorly focusing on the detection of methylation markers related to cancer development. For instance, Epi proLung BL Reflex Assay by Epigenomics helps in the diagnosis of lung cancer by determining methylation of SHOX2 biomarker gene.

Related Press Release@ Epigenetics Market Report

Epigenetics Market Report Highlights:

On the basis of product, reagents held the largest share in the market in 2017. They are projected to amount to approximately USD 7.06 billion by 2025 owing to increasing R&D activities in the field of epigenetics
The kits segment is expected to post a CAGR of over 20.0% due to the need for rapid and accurate detection techniques
DNA methylation, on the basis of technology, held the leading revenue share in the market in 2017, accounting for just over 47.0%. The rapid adoption of advanced techniques such as methylation-sensitive PCR (MSP) to improve diagnostics efficiency is poised to bolster the growth of the segment
North America commanded the leading position in the global arena with a share of 40.0% in 2017. The growth of the regional market can be attributed to the increasing prevalence of cancer and growing collaborations between large pharmaceutical firms for the development of improved therapeutics
Asia Pacific is estimated to register a noteworthy CAGR of 22.1% during the forecast period owing to the presence of a large target population coupled with high unmet clinical needs
Some of the major players of epigenetics market are Illumina; Abcam; Diagenode; Thermo Fisher Scientific; Merck; Zymo research; Qiagen; CellCentric Ltd; Chroma Therapeutics Ltd; Eisai Co. Ltd; Novartis International AG; Oncolys Biopharma Inc.; Syndax Pharmaceuticals, Inc.; Valirx Plc; and Sigma-Aldrich Corporation
Extensive R&D initiatives for the development of novel drugs and the presence of strong product pipeline are expected to further boost market growth over the forecast period.

Thursday 27 April 2023

Hematology Diagnostics Market Share, Growth and Future Analysis

The global Hematology Diagnostics Market size is expected to reach USD 9.39 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 5.85% over the forecast period. Increasing prevalence of blood disorders coupled with adoption of automated testing processes are projected to propel the market growth.

Automation of hematology diagnostics process have led to reduced turnaround time thereby accelerating the overall treatment regimen. Furthermore, automation has also led to reduced administrative errors and overall costs of diagnostic tests. Thus, it is expected to boost growth of the hematology testing market in the forthcoming years.

Dominance of hematology analyzers can be attributed to the presence of fully-automated analyzers which are objective, have high-throughput, and are cost-effective. Furthermore, these hematology analyzers can also detect atypical results and can improve measurable parameters such as red cell distribution width, platelet distribution, Reticulocyte (RET) counts, and nucleated red cells counts.

The advent of Point-Of-Care (PoC) hematology testing devices has led to improved diagnostic and patient outcomes. These devices are user-friendly and are available for use outside the hospital settings. This is anticipated to increase the acceptability and accessibility of hematology testing which, in turn, is anticipated to propel market growth.

Product recall and intense market competition leading to price wars are anticipated to hinder market growth. In 2018, Becton Dickinson (BD) and Company recalled Vacutainer EDTA Blood Collection Tubes owing to chemical interference with certain tests. This recall was classified as Class I recall, the most serious type of recall, by the Food and Drug Administration (FDA), thereby indicating that the use of these devices may cause serious injuries or death. Such product recalls can negatively affect the market growth.

Related Press Release@ Hematology Diagnostics Market Report

Hematology Diagnostics Market Report Highlights

Consumables emerged as the largest segment owing to increasing testing and diagnosis of blood disorders
Diagnostic labs segment is projected to expand at a lucrative CAGR over the forecast period owing to high prevalence of blood disorders
North America held the dominant market share in 2017 owing to favorable reimbursement scenario and presence of sophisticated technological facilities
Asia Pacific is projected to witness swift growth during the forecast period owing to the rising healthcare expenditure coupled with focus on quality healthcare infrastructure
Few of the key players in hematology testing market include Beckman Coulter, Inc.;Abbott Laboratories; F. Hoffmann-La Roche Ltd.; Siemens Healthineers; Mindray Medical International Limited; and Sysmex Corporation.

Antibiotic Resistance Market Worth $12.07 Billion by 2025 | CAGR: 5.6%

The global Antibiotic Resistance Market size is estimated to reach USD 12.07 billion by 2025. According to a new report by Grand View Research, Inc., it is anticipated to post a CAGR of 5.6% during the forecast period. Rising burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens has been driving the market.

Biotech companies that are developing therapies for antibiotic-resistant infections include Melinta Therapeutics, Achaogen, and Nabriva Therapeutics. On the other hand, majority of large pharmaceutical companies don’t find this market lucrative enough due to slower growth in revenues for marketed drugs and lower return on investments. For instance, Novartis recently discontinued development of its antibacterial drugs for antibiotic resistance.

Manufacturers can obtain the Qualified Infectious Disease Product (QIDP) designation, which escalates the clinical review process for antibacterial therapies targeting high priority pathogens. The QIDP designation enables faster access to targeted agents and was introduced under the GAIN (Generating Antibiotic Incentives Now) Act, passed in 2012 as an extension to the U.S. FDA Safety and Innovation Act. The legislation aims to encourage the development of novel therapies for growing burden and severity of infections with antibiotic resistance.

Related Press Release@ Antibiotic Resistance Market Report

Antibiotic Resistance Market Report Highlights

In 2017, the market by cUTI disease registered significant sales due to elevated rate of resistance in extended-spectrum beta-lactamase (ESBL)-producing and carbapenem-resistant Enterobacteriaceae and P. aeruginosa strains
The combination therapies segment, which includes fixed-dose combinations of beta lactams and beta lactamase inhibitors, is projected to witness the fastest growth rate over the forecast period
Infections due to E. coli pathogens that are ESBL-producing and carbapenem-resistant led in terms of sales revenue in 2017 due to high treatment cost
On the geographical front, North America was the dominant revenue contributor in the market in 2017. Improving reimbursement scenario with new technology add-on payment provision is promoting the use of novel products in this region
Among pharmaceutical companies, Merck, Allergan, and Pfizer were the key players with top-selling drugs in the antibiotic resistance market in 2017.

List of Key Players in Antibiotic Resistance Market

· Achaogen, Inc.

· Basilea Pharmaceutica Ltd.

· Melinta Therapeutics

· Tetraphase Pharmaceuticals, Inc.

· Theravance Biopharma, Inc.

· Wockhardt therapeutics

· Entasis Therapeutics

· PARATEK therapeutics

· Seres Therapeutics, Inc.

IVD Quality Control Market Worth $1.24 Billion By 2026 | CAGR: 4.1%

The global IVD quality control market size is expected to reach USD 1.24 billion by 2026, according to a new report by Grand View Research, Inc. The market is projected to witness a CAGR of 4.1% over the forecast period. Continually evolving technology-oriented changes in the diagnostics field and growing need to ensure patient safety necessitate the implementation of quality assurance programs in various medical disciplines including radiology and Point-of-Care (PoC) devices. Patients rely on self-testing IVD devices for long-term disease management and hence it is important for such devices to be checked, in terms of result reproducibility and validity, to guarantee patient safety.

Rising number of certified clinical laboratories offering dependable IVD-based diagnostic services directly correlates with increased patient confidence, thus driving the market. In addition to quality assessments, amendments to the regulatory framework are made intermittently to enhance the existing standards with the main objective of safeguarding qualitative superiority of the diagnostic services. In May 2016, the European Union passed an agreement to update the pre-existing regulations pertaining to IVD devices, wherein the updates were in concern with raising the patient safety levels, particularly for disabled persons. The presence of third-party agencies for independent assessment of the IVD devices is expected to elevate the current safety standards, which will drive the In Vitro Diagnostics (IVD) Quality Control market further.

Further key findings from the study suggest:

In 2018, the clinical chemistry was the second-largest application segment of the global IVD market, in terms of market share
Demand for preventive medicine and rapid transformation of clinical laboratories into highly automated and efficient businesses are some of the factors for the segment’s growth
Molecular diagnostics is projected to be the fastest-growing segment due to increasing technical complexity of molecular diagnostic testing and need for quality evaluation to ensure standards
These tests are of prime importance as the outcomes enable healthcare practitioners make critical treatment decisions
Hospitals was the largest segment in 2018 due to the presence of advanced technology-based devices like Next Generation Sequencing (NGS) and microarrays, and rising applications of the optimized quality-control procedures
North America was the dominant regional market in 2018 due to the presence of over 150,000 registered diagnostics labs and is likely to maintain the dominance throughout the forecast years
Siemens Healthcare GmbH; Roche Diagnostics; Alere, Inc.; Abbott Laboratories, Inc.; Qiagen N.V.; Bio-Rad Laboratories, Inc.; Quidel Corp.; Becton, Dickinson and Company; bioMerieux, Inc.; Sysmex Corp.; Sero AS; and Thermo Fisher Scientific, Inc. are some of the key companies in the global market

Computational Biology Market: Industry Demand, Analysis And Future Trends 2026

The global Computational Biology Market size is expected to reach USD 13.6 billion by 2026, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 21.3% during the forecast period. Rise in clinical studies in pharmacokinetics and pharmacogenomics for novel drug delivery and increase in the application of computational biology for bioinformatics R&D programs for the population based sequencing studies are fueling the market growth.

Rising use of computational tools in genomics, epi-genomics, proteomics, and meta-genomics to understand 3D protein structural analysis, protein-protein interactions, and gene sequencing and expression studies coupled with increasing research activities in drug designing and disease modeling is expected to drive the growth. However, lack of skilled resources to operate computational tools is expected to restrain the growth of the computational biology market during the forecast period.

Many pharmaceutical companies are seeking funding from angel investors. For instance, in February 2019, StemoniX Inc., the U.S. based provider of product and services for drug discovery and development, received funding of USD 14.40 million from a group of investors. Brightstone Venture Capital was the major financer and was later joined by Crescent Ridge Partners, Alumni Ventures Group, and Mayo Clinic. Similarly, in the same month, U.S. based Buffalo Niagara Medical Campus received funding of USD 5.0 million to speed up the discovery of new drugs. With this finding, the research institute is planning to procure and install drug discovery research instruments and other drug discovery platforms.

Related Press Release@ Computational Biology Market Report

Computational Biology Market Report Highlights

Cellular and biological simulation is expected to expand at the fastest CAGR of over 15.0% over the forecast period. The shift in sequencing studies towards further analysis of the nature of various biological proteins as a part of the development of personalized medicine, is projected drive the growth
Drug discovery and disease modelling applications led the market, accounting for 38.0% of the global market in terms of revenue in 2018. The factors responsible for this growth are extensive drug pipelines for the global drug manufacturing firms
North America was the largest regional market, accounted for more than 45.0% of the global revenue in 2018. Increase in research activities for drug discovery processes and innovations in biological computation tools are anticipated to drive the growth
Asia Pacific is anticipated to witness the fastest of around CAGR of 23.0% during the forecast period, due to increasing expenditure in the clinical studies for the pharmaco-kinetics and pharmaco-genomics
Some of the players operating in the computational biology market include Chemical Computing Group Inc.; Compugen Ltd.; Simulation Plus Inc.; Genedata AG; Certara; Insilico Biotechnology AG; Accelrys; Rhenovia Pharma SAS; Entelos; Nimbus Discovery LLC; and Rhenovia Pharma SAS.

Monday 24 April 2023

ePharmacy Market: Industry Demand, Analysis And Future Trends 2030

The global ePharmacy market size is expected to reach USD 249.9 billion by 2030 and is expected to grow at a CAGR of 19.5% over the forecast period, according to a new report by Grand View Research, Inc. Factors driving the adoption of ePharmacy include the improved access to online & web-based services, increasing awareness regarding e-commerce among consumers, rise in the number of internet users, and a surge in the aging population experiencing difficulty to visit pharmacies. In addition, benefits, such as affordability, convenience, and ease in the availability of medicines, are boosting the adoption of these platforms. High treatment costs are driving the demand for low-cost healthcare services, which, in turn, is bolstering the adoption of online pharmacies owing to the lucrative offers, such as price discounts, provided by them.

The COVID-19 pandemic has positively impacted the market growth and transformed the fortunes of ePharma companies owing to increasing consumer switch from traditional buying towards online purchases of general medications and medical devices, such as oximeters, thermometers, and health supplements. As per an article published by Economic Times in July 2021, the number of households utilizing ePharmacy services grew 2.5 times to 9.0 million during the pandemic. Moreover, the second wave of the Covid-19 epidemic has prompted a spike in demand for medical gadgets, personal protective equipment (PPE), as well as health supplements, and frequently accessible medications in the market.

In September 2020, UnitedHealth, purchased startup DivvyDose, a key player in the ePharmacy industry. DivvyDose, a competition to Amazon-owned PillPack, has been bought by UnitedHealth Group. Thus, the ePharmacy segment has also gained significant growth during the post lockdown period, as governments encouraged the delivery of medicines through e-commerce platforms as an essential service.

Related Press Release@ ePharmacy Market Report

ePharmacy Market Report Highlights

North America dominated the market in 2021 owing to the increased prevalence of chronic diseases, developed healthcare infrastructure, and penetration of IT in healthcare across the region. According to Clarivate Analytics, the usage of internet pharmacies has climbed by 17% in the U.S. during the previous year. Consumers aged 18 to 34 are the most likely to use it
Industry players in this market have significantly expanded their customer base as well as their product & service offerings to keep up with the growing needs of the consumers. As a result, in 2021 March, One of the U.K.'s digital prescription businesses has been bought by the corporation that runs the Rowlands drugstore chain and the Numark pharmacy membership business
The main focus of these players is on increasing the Customer Lifetime Value (CLTV) by catering to their healthcare needs in a comprehensive manner, as various online pharmacies have started offering additional services like e-diagnostics, e-consultation, and retailing of health & wellness products
Furthermore, a rise in the number of strategic initiatives is aiding market growth. For instance, in August 2020, Amazon India announced the launch of Amazon Pharmacy in Bengaluru, India. In June 2021, PharmEasy is purchasing a controlling share in Thyrocare Technologies, a diagnostics company. This alliance will provide huge potential and synergies for the whole Indian healthcare ecosystem of customers, physicians, and suppliers